[13] Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023. Retrieved December 15, 2023, from https://www.globenewswire.com/news-release/2023/12/11/2793986/0/en/Nexc...
2024年4月27日,中国医药教育协会与北京整合医学学会联合主办的第3届「和美天下」胰高糖素样肽-1(GLP-1)领域新进展学术交流会在上海、北京、广州、成都和武汉以线上和线下形式同时举行,国际著名糖尿病专家、曾获加拿大糖尿病协会终身成就奖及美国糖尿病协会(ADA)临床糖尿病研究杰出成就奖的 Hertzel C.Gerstein 教授...
[6] Brown, E. et al. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018, 100, 61-67. [7] O’Neil, P. M. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and...
The prescribing information for these drugs recommends monitoring exposed patients for depression or suicidal thoughts, and discontinuing the drug if symptoms develop (3).To what extent do GLP-1 agonists expose patients to a risk of depression, suicidal ideation, attempted suicide or suicide? This ...
时代在发展,糖尿病的治疗方式也一直在不断革新。 肠促胰岛素(incretin)类药物是糖尿病的重要治疗方式。除了胰高血糖素样肽1(GLP-1)受体激动剂在不断发展外,近年来,将葡萄糖依赖性促胰岛素多肽(GIP)和GLP-1相结合治疗糖尿病也取得重大突破。 Tirzepatide是一种GIP和GLP-1受体双重激动剂。近期,这款药物治疗2型糖...
Supplementary information Supplementary information About this article Cite this article Chen, Y., Xu, Yn., Ye, Cy.et al.GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.Acta Pharmacol Sin43, 1156–1166 (2022). https://doi.org/10.1038/s41401-021-00836-9 ...
Ro's tool aims to make GLP-1 supply information more transparent and accessible for everyone, regardless of whether they are enrolled in any of the company's programs. Telehealth companyRoon Wednesday launched anew trackerto help patients find a popular cla...
. These findings emphasize that targeted antagonism of NMDA receptor signalling lowers body weight independently of MC4R, indicating that this preclinical drug candidate might not only be effective in treating polygenic obesity but also holds potential as an effective weight loss strategy for patients ...
“This tool provides real-time information on how lifestyle choices such as food, activity, medication and stress can impact a patient’s body. We both benefit from this data, and it makes it easier for a patient to stay engaged with these changes in the short- and long-term.” ...
4.信达生物宣布mazdutide(IBI362)在中国2型糖尿病受试者中的III期临床研究完成首例受试者给药https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-a-phase-3-clinical-study-dreams-2-of-mazdutide-ibi362-in-chinese-patients-with-type-2-diabetes-301717820.html ...